

Letter to the Editor

Eczema and race as combined determinants for differential response to step-up asthma therapy

To the Editor:

The overall best step-up therapy for children inadequately controlled on low-dose inhaled steroids (ICS) is the addition of a long-acting β -agonist (LABA) as compared to increasing the ICS dose or adding a leukotriene receptor-antagonist (LTRA). However, this preference for LABA step-up may not be shared by all races or ethnicities. We performed a *post hoc* analysis of differential treatment responses in relation to baseline history of eczema and race in 163 children aged 6 to 17 years enrolled in the Best Add-on Therapy Giving Effective Response (BADGER) trial. All participants in this study had uncontrolled asthma on fluticasone 100 μ g twice daily at baseline and subsequently received 3 step-up therapies in random order for 16 weeks each: fluticasone 250 μ g twice daily (ICS step-up), fluticasone 100 μ g + salmeterol 50 μ g twice daily (LABA step-up), and fluticasone 100 μ g twice daily + montelukast 5 or 10 mg daily (LTRA step-up) in a blinded, randomized, triple cross-over design. Rank-ordered logistic regression modeling was used to examine which patient characteristics were predictive of different patterns of treatment rankings in a similar analysis as used in the original BADGER report.¹

In the BADGER trial, 98% of the participants with asthma uncontrolled on low-dose ICS had a differential response to the 3

step-up treatments. The best response for the entire study population was LABA step-up because this option was 1.5 times more likely to provide the best response compared with ICS or LTRA step-up. In the present *post hoc* analysis of the BADGER data, this observation of a better LABA response was shown to be related substantially to eczema status. There was a strong pattern of best responses to LABA step-up in children without a history of eczema regardless of race or ethnicity status. In children with a history of eczema, however, preferred responses to therapy depended on race/ethnicity ($P = .0002$). In the eczema subgroup, black participants ($N = 29$) responded best to ICS step-up, white Hispanics ($N = 19$) to LTRA step-up, and white non-Hispanics ($N = 31$) demonstrated equivalent responses to step-up LABA or LTRA therapy (Fig 1).

On the basis of this analysis, we speculate that children without a history of eczema respond best to step-up LABA therapy because their disease is less likely to be related to persistent airway inflammation. This hypothesis is supported by observations that the group with a history of eczema had more signs of atopic inflammation than did the noneczema group, including higher circulating eosinophils ($P < .015$), a greater number of positive perennial allergen skin test results ($P = .05$), and a trend toward higher serum IgE levels ($P = .11$) (Table 1). A recently published *post hoc* analysis of biomarker predictors in the BADGER study demonstrated that differential responses favoring LABA were related to a phenotype characterized by lower levels of inflammation (measured by lower levels of urinary leukotriene




FIG 1. Overall probability of best response to step-up therapies with ICS (red bars), LABA (blue bars), or an LTRA (orange bars) according to race/ethnicity by presence (A) and absence (B) of a history of eczema (active or past).

TABLE I. Baseline characteristics of 163 patients with and without a history of eczema enrolled in the BADGER study

Characteristic	Eczema (n = 85)	No eczema (n = 78)	P value
Age (y), mean $\pm$ SD	10.6 $\pm$ 3.0	11.1 $\pm$ 3.0	.34
Age at onset of early asthma symptoms (y), mean $\pm$ SD	2.6 $\pm$ 2.3	3.4 $\pm$ 3.1	.06
Height (cm), mean $\pm$ SD	143.2 $\pm$ 16.1	145.3 $\pm$ 18.8	.4
Weight (kg), mean $\pm$ SD	43.7 $\pm$ 18.5	46.6 $\pm$ 20.2	.35
Male gender, n (%)	50 (59)	56 (72)	.10*
Body mass index, (kg/m ²), mean $\pm$ SD	20.5 $\pm$ 4.9	21.1 $\pm$ 5.2	.4
Race or ethnic groups, n (%)			.3*
Black	29 (34)	16 (21)	
White Hispanic or Latino	19 (22)	20 (26)	
White non-Hispanic	31 (37)	36 (46)	
Other	6 (7)	6 (7)	
Number of (+) aeroallergen skin tests, mean $\pm$ SD	3.2 $\pm$ 2.3	2.8 $\pm$ 2.2	.26
Number of (+) perennial skin tests, mean $\pm$ SD	1.8 $\pm$ 1.4	1.4 $\pm$ 1.3	.05
Circulating eosinophil count (per mL), median (25th, 75th quartile)	347.1 (199.2, 532.6)	256.0 (150.8, 408.0)	.015†
Total serum IgE (kU/L), median (25th, 75th quartile)	347.0 (142.0, 716.3)	251.6 (65.5, 624.0)	.11†
Fraction of exhaled nitric oxide (FENO) (ppb), median (25th, 75th quartile)	10.3 (7.0, 20.7)	9.9 (6.6, 18.9)	.8†
LTE ₄ (pg per mg creatinine)/FENO (ppb), median (25th, 75th quartile)	5.2 (2.5, 10.4)	5.0 (2.9, 9.7)	.9†
LTE ₄ (pg per mg creatinine), median (25th, 75th quartile)	60.7 (40.6, 82.3)	59.0 (44.0, 82.8)	.9†
Prebronchodilator FEV ₁ (% predicted), mean $\pm$ SD	98.8 $\pm$ 13.3	97.3 $\pm$ 14.2	.5
Maximum bronchodilator response‡ (%) , mean $\pm$ SD	11.6 $\pm$ 10.2	11.8 $\pm$ 11.6	.9
Methacholine FEV ₁ PC ₂₀ , (mg/mL) median (25th, 75th quartile)	1.5 (0.6, 4.2)	1.7 (0.6, 4.3)	.8†
Asthma Control Test, mean $\pm$ SD	20.8 $\pm$ 2.8	20.1 $\pm$ 4.1	.2

LTE₄, Leukotriene E₄; ppb, parts per billion.

*P value determined using the χ^2 test.

†P value determined using the Kruskal-Wallis test.

‡Maximum bronchodilator response.

E₄) and greater peripheral airway disease measured by impulse oscillometry.² These studies are not directly comparable because the previous study reported changes in FEV₁ as the main outcome instead of the present composite outcome, yet one could argue that the broad patterns differentiating LABA responders from non-LABA responders are similar.

Although response to LABA was primarily related to eczema status, race appeared to differentiate ICS responders (better in black children) from LTRA responders (better in white children). A number of studies have reported a differential response to asthma therapy based on race,³⁻⁶ concluding that black asthmatic patients demonstrate a relatively poor response to ICS therapy than do white asthmatic patients. These studies perhaps infer that blacks are less likely to respond fully to low doses of ICS therapy and are therefore more likely to exhibit uncontrolled disease due to partially treated atopic airway inflammation, whereas uncontrolled asthma in white children might be more likely to reflect noneosinophilic inflammation or abnormal airway tone. This may partially explain why black children with eczema respond preferentially to an increase in ICS therapy compared with adding LABA or LTRA to low-dose ICS.

In contrast, black children had poor responses to LTRA therapy whether they had eczema or not. Inhibition of leukotriene activity by synthesis inhibitors or receptor antagonists has been established as an alternative for the treatment of patients with asthma. However, there are substantial variations in the treatment response possibly related to genetic variability. Drazen et al⁷ defined a family of DNA sequence variants in the core promoter of the gene responsible for the 5-lipoxygenase pathway (ALOX5), leading to decreased transcription, a relatively poor clinical response to antileukotriene therapy. Expression of some of these ALOX5 gene variants is higher in African Americans,

perhaps explaining the poor response to step-up LTRA therapy in the BADGER trial.⁸ Further studies examining the interaction between genetic variation, race, and response to LTRAs might be considered to test this hypothesis.

In conclusion, LABA step-up therapy is the preferred step-up therapy in asthmatic children without eczema. However, the preferred step-up therapy for those with eczema varies by race, with black children more likely to respond to increased ICS therapy, white Hispanics responding better to step-up LTRAs, and white non-Hispanics to step-up LABA or LTRA therapy. Given the limitations of this relatively small and exploratory analysis, these findings will require replication in a larger prospective study. If validated, these novel findings might provide a personalized approach in targeting interventions for children with uncontrolled asthma based on specific and easily obtainable clinical features such as a history of eczema and race/ethnicity.

Jonathan Malka, MD^{a,b}

David T. Mauger, PhD^c

Ronina Covar, MD^d

Nathan Rabinovitch, MD, MPH^d

Robert F. Lemanske, Jr, MD^d

Joseph D. Spahn, MD^d

Robert C. Strunk, MD^e

Robert S. Zeiger, MD, PhD^f

Wayne J. Morgan, MD^g

Stanley J. Szefer, MD^a

From ^athe Department of Pediatrics, National Jewish Health and University of Colorado Denver School of Medicine, Denver, Colo; ^bthe Pediatric Associates, Lauderdale Lakes, Fla; ^cthe Department of Health Evaluation Sciences, Pennsylvania State University, Hershey, Pa; ^dthe University of Wisconsin School of Medicine and Public Health, Madison, Wis; ^ethe Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, Wash; ^fthe Department of Allergy, Kaiser Permanente and the Department of

Pediatrics, University of California-San Diego, San Diego, Calif; and [§]Arizona Respiratory Center, University of Arizona, Tucson, Ariz. E-mail: szefflers@njhealth.org. This study was supported by grants from the National Heart, Lung, and Blood Institute (grant nos. HL064307, HL064288, HL064295, HL064287, HL064305, and HL064313), the National Institute of Allergy and Infectious Diseases (grant no. T32AI007635), and the Clinical Translational Science Award program of the National Center for Research Resources (NCRR) (grant no. UL1-RR025011 [Wisconsin] and grant no. UL1-RR024992 [St Louis]). This study was performed in part by the General Clinical Research Centers at Washington University School of Medicine (M01-RR00036), and the University of Wisconsin (M01-RR03186). This study was also supported by Colorado CTSA (grant no. UL1 RR025780 from NCRR/National Institutes of Health [NIH] and grant no. UL1 TR000154 from NIH/NCATS).

Disclosure of potential conflict of interest: J. Malka has received payment for lectures from Aerocrine and Thermo Fisher. D. T. Mauger has received research support from the National Heart, Lung, and Blood Institute (NHLBI) and has consultant arrangements with GlaxoSmithKline, Merck, and Boehringer-Ingelheim R. Covar has consultant arrangements and has received research support from GlaxoSmithKline. R. F. Lemanske has received research support from the University of Wisconsin, the NHLBI, and Pharmaxis; has received travel support from the American Academy of Allergy, Asthma & Immunology (AAAAI); is employed by the University of Wisconsin; has received consultant fees from Merck, Sepracor, SA Boney and Associates, GlaxoSmithKline, the American Institute of Research, Genentech, Double Helix Development, and Boehringer-Ingelheim; has received speakers honoraria from Michigan Public Health, Allegheny General Hospital, the American Academy of Pediatrics, West Allegheny Health, California Chapter 4, the Colorado Allergy Society, the Pennsylvania Allergy Society, Howard Pilgrim Health, the California Society of Allergy, the NYC Allergy Society, the World Allergy Organization, APAPARI, and the Western Society of Allergy, Asthma, and Immunology; has received payment for manuscript preparation from the AAAAI; and has received royalties from Elsevier and UpToDate. J. D. Spahn has received consulting fees or honoraria from GlaxoSmithKline and is employed by National Jewish Health. R. C. Strunk has received research support from the NHLBI. R. S. Zeiger has received research support from the NHLBI, Genentech, GlaxoSmithKline, Aerocrine, Merck, MedImmune, and Thermo Fisher; is a board member for DBV Technologies; has consultant arrangements with GlaxoSmithKline, Genentech, Novartis, the NHLBI/Penn State, Aerocrine, AstraZeneca, and the Allergen Research Corporation; and has stock/stock options in DBV Technologies. W. J. Morgan has received research support from the National Institutes of Health; has received travel support from the National Institutes of Health/University of Arizona; has consultant arrangements with Genentech and the Cystic Fibrosis Foundation; is employed by the University of Arizona; has

received research support from the National Institutes of Health, National Institutes of Health/Mount Sinai, Cystic Fibrosis Foundation/University of Washington, and the Cystic Fibrosis Foundation; has received payment for lectures from the American Thoracic Society, the AAAAI, the University of Tennessee, the University of Indiana, and the University of Alberta; and has received royalties from Elsevier. S. J. Szeffler has consultant arrangements with Merck, Genentech, Boehringer-Ingelheim, and GlaxoSmithKline; has received research support from GlaxoSmithKline; has received payment for lectures from Merck; has received payment for manuscript preparation from Genentech; and has submitted patents for beta adrennergic receptor polymorphism for the NHLBI Childhood Asthma Research and Education Network. N. Rabinovitch declares no relevant conflicts of interest.

REFERENCES

1. Lemanske R, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al, for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Step-up therapy for children with uncontrolled asthma while receiving inhaled corticosteroids. *N Engl J Med* 2010;362:975-85.
2. Rabinovitch N, Mauger DT, Reisdorph N, Covar R, Malka J, Lemanske RF Jr, et al. Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma. *J Allergy Clin Immunol* 2014;133:350-6.
3. Naqvi M, Thyne S, Choudhry S, Tsai HJ, Navarro D, Castro RA, et al. Ethnic-specific differences in bronchodilator responsiveness among African Americans, Puerto Ricans, and Mexicans with asthma. *J Asthma* 2007;44:639-48.
4. Naqvi M, Tcheurekdjian H, DeBoard JA, Williams LK, Navarro D, Castro RA, et al. Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients. *Ann Allergy Asthma Immunol* 2008;100:551-7.
5. Federico M, Covar R, Brown E, Leung DY, Spahn JD. Racial differences in T-lymphocyte response to glucocorticoids. *Chest* 2005;127:571-8.
6. Chan MTS, Leung DY, Szeffler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. *J Allergy Clin Immunol* 1998;101:594-601.
7. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. *N Engl J Med* 1999;340:197-206.
8. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. *Am J Respir Crit Care Med* 2006;173:379-85.

<http://dx.doi.org/10.1016/j.jaci.2014.03.039>